PURE Bioscience (PURE) stock price, revenue, and financials

PURE Bioscience market cap is $140.2 m, and annual revenue was $1.91 m in FY 2019

$140.2 M

PURE Mkt cap, 22-Sept-2020

$2.2 M

PURE Bioscience Revenue Q3, 2020
PURE Bioscience Gross profit (Q3, 2020)1.2 M
PURE Bioscience Gross profit margin (Q3, 2020), %56.2%
PURE Bioscience Net income (Q3, 2020)473 K
PURE Bioscience EBIT (Q3, 2020)474 K
PURE Bioscience Cash, 30-Apr-20202 M

PURE Bioscience Revenue

PURE Bioscience revenue was $1.91 m in FY, 2019

Embed Graph

PURE Bioscience Income Statement

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

257.0k221.0k207.0k110.0k263.0k258.0k115.0k41.0k261.0k117.0k273.0k109.0k186.0k176.0k403.0k531.0k447.0k338.0k464.0k411.0k390.0k590.0k394.0k312.0k398.0k349.0k2.2m

Cost of goods sold

129.0k40.0k37.0k31.0k57.0k67.0k36.0k20.0k89.0k45.0k111.0k65.0k54.0k48.0k116.0k265.0k134.0k132.0k146.0k161.0k166.0k203.0k160.0k117.0k156.0k142.0k972.0k

Gross profit

128.0k181.0k170.0k79.0k206.0k191.0k79.0k21.0k172.0k72.0k162.0k44.0k132.0k128.0k287.0k266.0k313.0k206.0k318.0k250.0k224.0k387.0k234.0k195.0k242.0k207.0k1.2m

Gross profit Margin, %

50%82%82%72%78%74%69%51%66%62%59%40%71%73%71%50%70%61%69%61%57%66%59%63%61%59%56%

R&D expense

493.0k489.0k439.0k395.0k406.0k304.0k234.0k289.0k248.0k176.0k215.0k171.0k236.0k238.0k205.0k248.0k214.0k222.0k144.0k120.0k117.0k97.0k67.0k85.0k82.0k60.0k85.0k

General and administrative expense

2.0m1.9m1.6m1.5m1.6m1.5m993.0k1.2m1.3m1.2m1.2m1.2m1.1m1.4m1.4m1.3m1.3m1.3m1.4m1.4m1.2m1.1m1.0m886.0k1.3m810.0k690.0k

Operating expense total

2.5m2.4m2.0m1.9m2.0m1.8m3.9m3.2m2.4m2.0m1.9m2.1m2.0m2.4m1.8m1.9m1.7m1.8m2.2m2.3m1.9m3.0m1.5m1.1m1.4m870.0k775.0k

EBIT

(2.4m)(2.2m)(1.8m)(1.8m)(1.8m)(1.6m)(3.8m)(3.2m)(2.2m)(1.9m)(1.7m)(2.1m)(1.9m)(2.3m)(1.5m)(1.6m)(1.4m)(1.6m)(1.9m)(2.0m)(1.7m)(2.6m)(1.3m)(912.0k)(1.1m)(663.0k)474.0k

EBIT margin, %

(919%)(992%)(882%)(1629%)(688%)(611%)(3332%)(7856%)(837%)(1650%)(636%)(1927%)(1001%)(1284%)(369%)(301%)(314%)(471%)(415%)(493%)(439%)(434%)(328%)(292%)(284%)(190%)21%

Interest expense

1.0k3.0k588.0k1.0k2.0k739.0k135.0k4.0k9.0k958.0k8.6m1.5m146.0k468.0k145.0k412.0k1.0k19.0k3.0k4.0k961.0k5.0k1.0k

Interest income

1.0k

Net Income

(2.4m)(2.2m)(1.8m)(2.2m)(1.8m)(1.5m)(3.8m)(2.5m)(2.0m)(1.9m)(1.7m)(2.1m)(2.8m)(10.9m)30.0k(1.7m)(936.0k)(1.7m)(2.3m)(2.0m)(1.7m)(2.6m)(1.3m)(1.9m)(1.1m)(666.0k)473.0k

PURE Bioscience Balance Sheet

Annual

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

992.0k626.0k289.0k2.5m920.0k410.0k1.1m236.0k416.0k5.3m3.9m2.5m6.1m6.7m5.4m4.1m3.9m2.7m3.2m2.1m1.0m776.0k335.0k340.0k904.0k246.0k2.0m

Accounts Receivable

119.0k16.0k193.0k64.0k95.0k29.0k31.0k9.0k34.0k47.0k40.0k86.0k93.0k106.0k68.0k146.0k142.0k185.0k143.0k146.0k192.0k353.0k129.0k134.0k220.0k156.0k1.6m

Prepaid Expenses

189.0k482.0k432.0k80.0k85.0k110.0k231.0k221.0k194.0k154.0k75.0k33.0k150.0k88.0k312.0k331.0k189.0k154.0k175.0k104.0k52.0k71.0k49.0k28.0k30.0k15.0k10.0k

Inventories

850.0k889.0k901.0k864.0k836.0k781.0k430.0k429.0k387.0k231.0k186.0k207.0k219.0k237.0k320.0k348.0k340.0k348.0k274.0k267.0k275.0k209.0k205.0k195.0k162.0k141.0k282.0k

Current Assets

2.2m2.0m1.8m3.5m1.9m1.3m1.8m895.0k1.0m5.8m4.2m2.9m6.6m7.2m6.2m5.0m4.6m3.5m3.9m2.7m1.6m1.5m793.0k772.0k1.4m633.0k4.0m

PP&E

357.0k326.0k291.0k226.0k199.0k171.0k127.0k115.0k42.0k28.0k90.0k97.0k83.0k231.0k407.0k495.0k568.0k574.0k530.0k515.0k487.0k443.0k416.0k388.0k333.0k351.0k328.0k

Total Assets

4.4m4.2m4.1m5.7m4.1m3.5m3.3m2.4m2.5m7.1m5.6m4.2m7.8m8.6m7.6m6.4m6.1m4.9m5.2m4.0m2.8m2.5m1.8m1.7m2.2m1.5m4.8m

Accounts Payable

1.0m1.5m1.9m2.1m621.0k848.0k771.0k629.0k529.0k510.0k510.0k533.0k384.0k582.0k522.0k654.0k424.0k574.0k425.0k449.0k486.0k420.0k525.0k386.0k749.0k589.0k1.3m

Short-term debt

86.0k231.0k503.0k

Current Liabilities

1.4m1.9m2.3m2.6m1.2m1.5m2.3m1.5m1.2m875.0k817.0k763.0k7.6m18.5m10.5m2.8m2.2m2.4m637.0k682.0k623.0k572.0k650.0k523.0k877.0k692.0k1.5m

Total Debt

86.0k231.0k503.0k

Total Liabilities

1.4m1.9m2.3m2.6m2.4m2.6m3.1m1.5m1.2m887.0k828.0k773.0k7.6m18.5m10.5m2.8m2.2m2.4m647.0k699.0k638.0k584.0k660.0k530.0k877.0k692.0k1.5m

Common Stock

411.0k445.0k480.0k110.0k110.0k123.0k239.0k259.0k286.0k398.0k402.0k412.0k553.0k602.0k622.0k649.0k627.0k628.0k680.0k681.0k681.0k716.0k717.0k741.0k800.0k800.0k869.0k

Preferred Stock

Additional Paid-in Capital

58.6m60.1m61.3m67.6m68.1m68.8m74.0m77.1m79.6m89.0m89.2m90.0m91.4m92.1m99.0m107.9m109.2m109.5m115.7m116.4m117.0m120.7m121.2m123.1m125.2m125.2m127.2m

Retained Earnings

(56.0m)(58.2m)(60.0m)(64.7m)(66.5m)(68.0m)(74.0m)(76.5m)(78.5m)(83.2m)(84.9m)(87.0m)(91.7m)(102.6m)(102.5m)(105.0m)(105.9m)(107.6m)(111.8m)(113.8m)(115.5m)(119.5m)(120.8m)(122.7m)(124.6m)(125.3m)(124.8m)

Total Equity

3.0m2.3m1.8m3.1m1.7m906.0k211.0k890.0k1.3m6.2m4.7m3.4m235.0k(9.9m)(2.9m)3.6m3.9m2.5m4.6m3.3m2.2m2.0m1.1m1.2m1.4m776.0k3.3m

Financial Leverage

1.5 x1.8 x2.3 x1.8 x2.4 x3.9 x15.6 x2.7 x1.9 x1.1 x1.2 x1.2 x33.3 x-0.9 x-2.6 x1.8 x1.6 x2 x1.1 x1.2 x1.3 x1.3 x1.6 x1.4 x1.6 x1.9 x1.5 x

PURE Bioscience Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(7.7m)(11.0m)(7.6m)(14.4m)(6.3m)(7.4m)(6.6m)

Depreciation and Amortization

311.0k248.0k206.0k219.0k276.0k285.0k241.0k

Accounts Receivable

82.0k(29.0k)(142.0k)(74.0k)(34.0k)22.0k(98.0k)

Inventories

149.0k(12.0k)42.0k(143.0k)27.0k37.0k20.0k

Accounts Payable

962.0k(96.0k)(955.0k)(131.0k)(59.0k)103.0k(40.0k)

Cash From Operating Activities

(3.9m)(6.3m)(6.1m)(5.0m)(4.6m)(3.9m)(3.0m)

Purchases of PP&E

(12.0k)(21.0k)(81.0k)(390.0k)(206.0k)(19.0k)(7.0k)

Cash From Investing Activities

(231.0k)(46.0k)(107.0k)(405.0k)(226.0k)(34.0k)(13.0k)

Short-term Borrowings

(43.0k)(528.0k)

Long-term Borrowings

(1.3m)

Cash From Financing Activities

3.3m6.4m7.4m9.3m1.2m3.1m2.6m

Net Change in Cash

(845.0k)54.0k1.2m3.9m(3.6m)(789.0k)(453.0k)

Interest Paid

Income Taxes Paid

1.6k4.0k1.6k2.0k7.0k3.0k5.0k

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(2.4m)(4.6m)(1.8m)(2.2m)(4.0m)(5.5m)(3.8m)(6.3m)(8.4m)(1.9m)(3.7m)(5.8m)(2.8m)(13.7m)(13.7m)(1.7m)(2.7m)(4.4m)(2.3m)(4.4m)(6.1m)(2.6m)(3.9m)(5.7m)(1.1m)(1.8m)(1.3m)

Depreciation and Amortization

117.0k216.0k73.0k158.0k236.0k73.0k140.0k196.0k51.0k103.0k154.0k51.0k103.0k154.0k65.0k134.0k204.0k71.0k142.0k213.0k71.0k143.0k191.0k52.0k100.0k145.0k

Accounts Receivable

(69.0k)34.0k(273.0k)(273.0k)(273.0k)(13.0k)9.0k(16.0k)7.0k(39.0k)96.0k83.0k121.0k117.0k121.0k78.0k154.0k151.0k105.0k(78.0k)146.0k141.0k153.0k217.0k(1.2m)

Inventories

11.0k(28.0k)(3.0k)25.0k80.0k(65.0k)(64.0k)(22.0k)18.0k63.0k42.0k(12.0k)(30.0k)(113.0k)2.0k10.0k2.0k(1.0k)(20.0k)17.0k(12.0k)(8.0k)2.0k15.0k36.0k(105.0k)

Accounts Payable

438.0k935.0k209.0k234.0k487.0k42.0k(275.0k)(588.0k)(955.0k)(1.0m)(1.1m)(250.0k)(33.0k)(125.0k)147.0k(36.0k)58.0k(38.0k)7.0k(52.0k)(206.0k)(128.0k)(255.0k)139.0k(46.0k)753.0k

Cash From Operating Activities

(1.5m)(2.8m)(1.2m)(2.7m)(3.5m)(2.2m)(4.0m)(5.4m)(2.2m)(3.5m)(4.9m)(1.3m)(2.5m)(3.7m)(1.0m)(2.2m)(3.4m)(1.0m)(2.1m)(3.2m)(1.1m)(1.5m)(2.3m)(324.0k)(938.0k)(1.2m)

Purchases of PP&E

(9.0k)(3.0k)(11.0k)(12.0k)(11.0k)(21.0k)(21.0k)(68.0k)(81.0k)(154.0k)(337.0k)(76.0k)(173.0k)(205.0k)(9.0k)(20.0k)(19.0k)(8.0k)(8.0k)(6.0k)(44.0k)(44.0k)

Cash From Investing Activities

(39.0k)(88.0k)(80.0k)(142.0k)(203.0k)(23.0k)(82.0k)(34.0k)(4.0k)(74.0k)(97.0k)(4.0k)(162.0k)(348.0k)(83.0k)(183.0k)(216.0k)(12.0k)(24.0k)(31.0k)(8.0k)(8.0k)(10.0k)(44.0k)(44.0k)

Short-term Borrowings

(22.0k)(21.0k)(528.0k)(528.0k)

Long-term Borrowings

(1.3m)(1.3m)(22.0k)(21.0k)

Cash From Financing Activities

720.0k1.7m2.9m2.9m3.3m3.3m4.3m5.8m7.5m7.4m7.4m6.0m8.0m8.2m1.1m1.1m2.6m2.6m2.6m993.0k993.0k1.8m830.0k830.0k2.8m

Net Change in Cash

(802.0k)(1.2m)1.6m43.0k(467.0k)1.0m204.0k384.0k5.2m3.8m2.4m4.7m5.4m4.1m(1.1m)(1.3m)(2.5m)1.6m489.0k(622.0k)(75.0k)(516.0k)(511.0k)506.0k(152.0k)1.6m

Interest Paid

22.0k

Income Taxes Paid

1.0k1.0k4.0k4.0k1.6k1.6k2.0k2.0k2.0k2.0k2.0k2.0k2.0k2.0k

PURE Bioscience Ratios

USDQ1, 2012

Financial Leverage

1.5 x